Compare DexCom, Inc. (DXCM) vs GE Vernova Inc (GEV) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

GE Vernova (GEV) trades at $1,038, down 2.63% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong profitability with 23.81% net income margin and 83.23% ROE, though valuation metrics appear elevated with P/E of 30.84 and EV/EBITDA of 109.82. Recent earnings showed volatility with Q1 2026 beating expectations by a wide margin, while the company prepares for Q2 2026 results amid significant AI-driven power demand growth.

The outlook remains positive with analyst consensus strongly bullish (21 buy ratings, 0 sell) and $1,260 price target representing 21% upside. Key opportunities include AI data center power demand and $11 billion investment push, while risks include wind segment pressures and elevated valuation multiples that may limit near-term upside potential despite strong fundamentals.